The Cluster Randomized Trial of PSA Testing for Prostate Cancer (CAP) [19], reporting data at 10 years, and the randomized Prostate, Lung, Colorectal and Ovarian screening trial (PLCO) [20], reporting data at 16 years, did show an increase in the detection of low-risk prostate cancer. This evidence concerns the gene KLK3 and prostate cancer.